RUNX1 and acute myeloid leukemia: Additionally, RUNX1 is a translocation partner contributing to numerous fusion oncogenes in AML, of which RUNX1-ETO resulting from t(8;21) is the most common, presenting in 12% of cases with de novo AML (48).